Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxytocin for psychosocial stress in breast cancer survivors
2024-519383-40-00Phase 3Authorised
- Sponsor
- UZ Leuven
- Start
- Jan 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3 trial of oxytocin in breast cancer (2 arms), sponsored by UZ Leuven. Primary endpoint: Self-perceived emotional stress. Planned start Jan 2026; status: authorised.
02
Drugs
oxytocin
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-519383-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519383-40-00.